ALACHUA, FL--(Marketwired - April 02, 2015) - CTD Holdings, Inc. (CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that it has amended its agreement with Medical Need Europe (MNE) such that MNE will be the exclusive distributor in Europe of Trappsol® Cyclo™ and any new cyclodextrin-based Orphan Drug Designated treatments that CTD may develop in the future.
MNE, which is based in Stockholm, Sweden, currently is the exclusive European distributor of CTD's orphan drug designated Trappsol® Cyclo™ for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children. The MNE territory includes 44 countries in which the product is currently available on a compassionate-use "named patient" basis, following special approval from the national regulatory authorities on request from a prescribing physician. Patients are currently receiving Trappsol® Cyclo™ in Norway, Bulgaria, Spain, and Switzerland and a request from Turkey is currently being processed.
"CTD is committed to providing Trappsol® Cyclo™ as quickly as possible to any patient or family who requests it, while taking care to work through all appropriate regulatory and health agencies," said CTD President and CEO Dr. Jeffrey Tate. "We are pleased to work with MNE in this expanded relationship for the benefit of patients and families across Europe."
About the CTD Holdings, Inc.:
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com